

TABLE 1—ESTABLISHED LIST OF THE CHEMICALS AND CHEMICAL COMPOUNDS IDENTIFIED BY FDA AS HARMFUL AND POTENTIALLY HARMFUL CONSTITUENTS IN TOBACCO PRODUCTS AND TOBACCO SMOKE—Continued

Constituent	Carcinogen (CA), respiratory toxicant (RT), cardiovascular toxicant (CT), reproductive or developmental toxicant (RDT), addictive (AD)
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole) .....	CA
Hydrazine .....	CA, RT
Hydrogen cyanide .....	RT, CT
Indeno[1,2,3-cd]pyrene .....	CA
IQ (2-Amino-3-methylimidazo[4,5-f]quinoline) .....	CA
Isoprene .....	CA
Lead .....	CA, CT, RDT
MeA- $\alpha$ -C (2-Amino-3-methyl)-9H-pyrido[2,3-b]indole) .....	CA
Mercury .....	CA, RDT
Methyl ethyl ketone .....	RT
5-Methylchrysene .....	CA
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) .....	CA
Naphthalene .....	CA, RT
Nickel .....	CA, RT
Nicotine .....	RDT, AD
Nitrobenzene .....	CA, RT, RDT
Nitromethane .....	CA
2-Nitropropane .....	CA
N-Nitrosodiethanolamine (NDELA) .....	CA
N-Nitrosodiethylamine .....	CA
N-Nitrosodimethylamine (NDMA) .....	CA
N-Nitrosomethylethylamine .....	CA
N-Nitrosomorpholine (NMOR) .....	CA
N-Nitrosornicotine (NNN) .....	CA
N-Nitrosopiperidine (NPIP) .....	CA
N-Nitrosopyrrolidine (NPYR) .....	CA
N-Nitrososarcosine (NSAR) .....	CA
Nornicotine .....	AD
Phenol .....	RT, CT
PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) .....	CA
Polonium-210 .....	CA
Propionaldehyde .....	RT, CT
Propylene oxide .....	CA, RT
Quinoline .....	CA
Selenium .....	RT
Styrene .....	CA
o-Toluidine .....	CA
Toluene .....	RT, RDT
Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole) .....	CA
Trp-P-2 (1-Methyl-3-amino-5H-pyrido[4,3-b]indole) .....	CA
Uranium-235 .....	CA, RT
Uranium-238 .....	CA, RT
Vinyl acetate .....	CA, RT
Vinyl chloride .....	CA

Dated: March 23, 2012.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2012-7727 Filed 3-30-12; 11:15 am]

BILLING CODE 4160-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2012-N-0001]

### Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration

(FDA). The meeting will be open to the public.

*Name of Committee:* Peripheral and Central Nervous System Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the Agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on May 24, 2012, from 8:30 a.m. to 5 p.m.

*Location:* FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center (Rm. 1503), 10903 New Hampshire Ave., Silver Spring, MD 20993-0002. Information regarding

special accommodations due to a disability, visitor parking, and transportation may be accessed at: <http://www.fda.gov/AdvisoryCommittees/default.htm>; under the heading "Resources for You," click on "Public Meetings at the FDA White Oak Campus." Please note that visitors to the White Oak Campus must enter through Building 1.

**Contact Person:** Glendolynn S. Johnson, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., WO31-2417, Silver Spring, MD 20993-0002, (301) 796-9001, fax: (301) 847-8533, email: [PCNS@fda.hhs.gov](mailto:PCNS@fda.hhs.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

**Agenda:** The committee will discuss new drug application (NDA) 202737, for tafamidis meglumine capsules, proposed trade name VYNDAQEL, submitted by FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc. The proposed indication is for the treatment of transthyretin (TTR) familial amyloid polyneuropathy.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee link.

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before May 10, 2012. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those individuals interested in making formal oral presentations should notify the contact

person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before May 2, 2012. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by May 3, 2012.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Glendolynn S. Johnson at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at <http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: March 29, 2012.

**Jill Hartzler Warner,**

*Acting Associate Commissioner for Special Medical Programs.*

[FR Doc. 2012-7967 Filed 4-2-12; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HOMELAND SECURITY

[DHS Docket No. ICEB-2012-0002]

RIN 1653-ZA04

### Employment Authorization for Syrian F-1 Nonimmigrant Students Experiencing Severe Economic Hardship as a Direct Result of Civil Unrest in Syria Since March 2011

**AGENCY:** U.S. Immigration and Customs Enforcement; DHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces that the Secretary of Homeland Security

(Secretary) has suspended certain regulatory requirements for F-1 nonimmigrant students whose country of citizenship is Syria and who are experiencing severe economic hardship as a direct result of the civil unrest in Syria since March 2011. The Secretary has determined that a suspension of certain regulatory requirements for Syrian citizens who are F-1 nonimmigrant students is warranted because it will provide relief to these F-1 students so they may obtain employment authorization, work an increased number of hours while school is in session, and reduce their course load while continuing to maintain their F-1 student status. F-1 students who are granted employment authorization by means of this notice will be deemed to be engaged in a "full course of study" for the duration of their employment authorization, provided that they satisfy the minimum course load requirement described in this notice.

**DATES:** This notice is effective April 3, 2012 and will remain in effect until October 3, 2013.

**FOR FURTHER INFORMATION CONTACT:** Louis Farrell, Director, Student and Exchange Visitor Program; MS 5600, U.S. Immigration and Customs Enforcement, 500 12th Street SW., Washington, DC 20536-5600; (703) 603-3400. This is not a toll-free number. Program information can be found at <http://www.ice.gov/sevis/>.

### SUPPLEMENTARY INFORMATION:

#### What action is DHS taking under this notice?

The Secretary of Homeland Security (Secretary) is exercising her authority under 8 CFR 214.2(f)(9) to temporarily suspend the applicability of certain requirements governing on-campus and off-campus employment. F-1 students granted employment authorization by means of this notice will be deemed to be engaged in a "full course of study" for the duration of their employment authorization if they satisfy the minimum course load set forth in this notice. See 8 CFR 214.2(f)(6)(i)(F).

#### Who is covered by this notice?

This notice applies exclusively to F-1 students whose country of citizenship is Syria and who were lawfully present in the United States in F-1 nonimmigrant status on April 3, 2012 under section 101(a)(15)(F)(i) of the Immigration and Nationality Act (INA), 8 U.S.C. 1101(a)(15)(F)(i) and (1) are enrolled in an institution that is Student and Exchange Visitor Program (SEVP) certified for enrollment for F-1 students; (2) are currently maintaining